 3. Patients must have high-grade serous or endometrioid or high-grade predominantly serous or endometrioid histology, regardless of HRD or germline breast cancer susceptibility gene gBRCA mutation status. Patients with non mucinous epithelial ovarian cancer and gBRCA mutation are eligible. 